$2.1 Billion is the total value of BB BIOTECH AG's 24 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Buy | Celgene Corp | $362,353,000 | +18.8% | 4,219,298 | +93.1% | 17.22% | +9.5% |
| GILD | Sell | Gilead Sciences Inc. | $289,231,000 | +16.2% | 3,488,496 | -0.7% | 13.74% | +7.1% |
| INCY | Buy | Incyte Corp | $235,004,000 | +6.2% | 4,163,790 | +0.7% | 11.17% | -2.1% |
| ISIS | Buy | Isis Pharmaceuticals Inc. | $231,040,000 | -15.1% | 6,706,526 | +6.4% | 10.98% | -21.8% |
| VRTX | Vertex Pharmaceuticals Inc. | $132,973,000 | +33.9% | 1,404,445 | 0.0% | 6.32% | +23.4% | |
| MDVN | Buy | Medivation Inc. | $115,597,000 | +23.0% | 1,499,706 | +2.7% | 5.49% | +13.4% |
| ALXN | Alexion Pharmaceuticals Inc. | $113,661,000 | +2.7% | 727,428 | 0.0% | 5.40% | -5.3% | |
| GEVA | Sell | Synageva BioPharma Corp. | $94,160,000 | +20.7% | 898,476 | -4.4% | 4.47% | +11.3% |
| REGN | Buy | Regeneron Pharmaceuticals Inc. | $65,816,000 | -1.7% | 233,000 | +4.5% | 3.13% | -9.4% |
| PCYC | Buy | Pharmacyclics Inc. | $65,627,000 | +2.9% | 731,542 | +14.9% | 3.12% | -5.2% |
| HALO | Buy | Halozyme Therapeutics Inc. | $57,764,000 | -19.4% | 5,846,564 | +3.6% | 2.74% | -25.7% |
| NBIX | Buy | Neurocrine Biosciences Inc. | $45,789,000 | -5.1% | 3,086,552 | +3.0% | 2.18% | -12.5% |
| ALNY | Buy | Alnylam Pharmaceuticals Inc. | $39,247,000 | +24.0% | 621,288 | +31.8% | 1.86% | +14.3% |
| PBYI | Buy | Puma Biotechnology Inc. | $38,081,000 | +209.9% | 576,991 | +389.0% | 1.81% | +185.8% |
| IMGN | ImmunoGen Inc. | $37,515,000 | -20.6% | 3,165,816 | 0.0% | 1.78% | -26.8% | |
| RDUS | New | Radius Health Inc | $35,686,000 | – | 2,745,040 | +100.0% | 1.70% | – |
| THRX | Buy | Theravance Inc. | $27,792,000 | +1.1% | 933,244 | +5.1% | 1.32% | -6.8% |
| AGIO | New | Agios Pharmaceuticals Inc. | $23,185,000 | – | 506,000 | +100.0% | 1.10% | – |
| CLVS | Buy | Clovis Oncology Inc | $23,115,000 | -31.6% | 558,188 | +14.3% | 1.10% | -37.0% |
| TSRO | Buy | Tesaro Inc. | $21,920,000 | +23.0% | 704,582 | +16.5% | 1.04% | +13.4% |
| INFI | Buy | Infinity Pharmaceuticals Inc. | $19,183,000 | +24.0% | 1,505,737 | +15.8% | 0.91% | +14.4% |
| ECYT | Endocyte Inc. | $16,235,000 | -72.3% | 2,463,522 | 0.0% | 0.77% | -74.5% | |
| ACHN | Achillion Pharmaceuticals Inc. | $13,470,000 | +130.1% | 1,779,340 | 0.0% | 0.64% | +111.9% | |
| CBSTZ | Cubist Pharmaceuticals Inc.right 99/99/9999 | $101,000 | -82.3% | 876,273 | 0.0% | 0.01% | -82.8% | |
| ARIA | Exit | Ariad Pharmaceuticals Inc. | $0 | – | -171,517 | -100.0% | -0.07% | – |
| IDIX | Exit | Idenix Pharmaceuticals Inc. | $0 | – | -1,250,000 | -100.0% | -0.39% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biotech Focus N.V. #1
- Biotech Invest N.V. #2
- Biotech Target N.V. #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-07
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Kezar Life Sciences, Inc. | February 14, 2023 | 3,000,000 | 4.4% |
| Mersana Therapeutics, Inc. | February 14, 2023 | 4,066,200 | 4.1% |
| Molecular Templates, Inc. | February 14, 2023 | 11 | 19.9% |
| Myovant Sciences Ltd. | February 14, 2023 | 5,872,639 | 6.0% |
| Scholar Rock Holding Corp | February 14, 2023 | 2,132,725 | 4.1% |
| Radius Health, Inc.Sold out | August 30, 2022 | 0 | 0.0% |
| Cidara Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| Voyager Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| HALOZYME THERAPEUTICS, INC. | February 12, 2021 | 3,970,000 | 2.9% |
| Intra-Cellular Therapies, Inc. | February 12, 2021 | 3,538,419 | 4.4% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-15 |
| SC 13G | 2024-04-22 |
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.